Recherche: Tesamorelin

FDA-approved GHRH analog for HIV-associated lipodystrophy

Tesamorelin Research Papers & Clinical Studies

Tesamorelin is a peptide studied for its potential therapeutic effects. FDA-approved GHRH analog for HIV-associated lipodystrophy This page indexes all published research papers, clinical trials, and scientific studies related to Tesamorelin that are available in the PepsReview research library. Each paper includes metadata such as journal name, publication year, citation count, study type, and a summary of key findings. Where available, we provide direct links to the original publication and DOI references.

Researchers can use this index to quickly locate evidence supporting specific Tesamorelin applications, compare study designs, and evaluate the strength of clinical evidence. Papers are sorted by relevance and citation count. There are currently 3 research papers indexed for Tesamorelin.

For vendor pricing, user reviews, and a complete peptide profile including mechanism of action, benefits, side effects, and regulatory status, visit the main Tesamorelin profile page.

Tesamorelin

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy

Drugs 2011 300 Review

Tesamorelin is the first and only approved treatment for reducing excess abdominal fat in HIV lipodystrophy, significantly reducing visceral adipose tissue over 26 weeks.

Spotlight on tesamorelin in HIV-associated lipodystrophy

BioDrugs 2011 300 Review

Tesamorelin effectively reduced visceral adipose tissue in two 26-week trials without affecting subcutaneous fat, the only approved treatment for HIV lipodystrophy.

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

Ann Pharmacother 2012 280 Review

Review of tesamorelin, an FDA-approved GHRH analog (2010), for treating HIV-associated lipodystrophy, evaluating efficacy and safety from published literature.